动态18F-FET-PET中达峰时间的识别作为IDH1/2突变型弥漫性星形细胞瘤特异性预后标志物
本研究纳入300例新诊断WHO 2007 II-IV级胶质瘤患者,诊断时行18F-FET-PET,按IDH1/2突变和1p/19q共缺失状态分为4个亚组,分析TTPmin等影像因素与PFS和OS的关系。结果显示TTPmin以17.5分钟为界,TTPmin>17.5分钟者PFS和OS显著更长,且较长中位TTPmin与IDH1/2突变-1p/19q非共缺失组预后改善相关。
要点
- TTPmin>17.5分钟者PFS和OS显著更长(PFS和OS均P<0.001)。
- 较长中位TTPmin与IDH1/2突变-1p/19q非共缺失组预后改善相关。
- 18F-FET-PET动态分析可识别分子标志物分析尚不能区分的预后亚组。
核心结论
- 18F-FET-PET动态分析可定义IDH1/2突变-1p/19q非共缺失胶质瘤中预后不同的亚组,而这些亚组目前尚不能通过分子标志物分析区分。
研究设计与样本
- 研究纳入300例新诊断WHO 2007 II-IV级胶质瘤患者,诊断时行18F-FET-PET imaging,按IDH1/2突变和1p/19q共缺失状态分为4个亚组。
- 采用单因素和多因素回归分析年龄、Karnofsky体能评分、治疗、TTPmin和TBRmax与PFS和OS的关系。
主要发现
- PFS和OS在IDH1/2突变-1p/19q共缺失亚组最长,其次为IDH1/2突变-1p/19q非共缺失、IDH1/2野生型和GBM(P<0.001)。
- 以17.5分钟为cutoff,TTPmin>17.5分钟的患者PFS和OS显著更长(PFS和OS均P<0.001)。
- 较低TBRmax值或无18F-FET uptake也与整个队列的良好结局相关。
- 亚组分析中,较长中位TTPmin与IDH1/2突变-1p/19q非共缺失组的预后改善相关。
关键数值与推荐
- TTPmin cutoff为17.5分钟,TTPmin>17.5分钟组PFS和OS显著更长(P<0.001 for PFS and OS)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stratification of glioma according to isocitrate dehydrogenase 1/2 (IDH1/2) mutation and 1p/19q codeletion status has gained major importance in the new World Health Organization (WHO) classification. Parameters derived from uptake dynamics of 18F-fluoro-ethyl-tyrosine PET (18F-FET-PET) such as minimal time-to-peak (TTPmin) allow discrimination between different prognostic glioma subgroups, too. The present study is aimed at exploring whether TTPmin analysis provides prognostic information beyond the WHO classification. METHODS: Three hundred patients with newly diagnosed WHO 2007 grades II-IV gliomas with 18F-FET-PET imaging at diagnosis were grouped into 4 subgroups (IDH1/2 mut-1p/19q codel; IDH1/2 mut-1p/19q non-codel; IDH1/2 wildtype WHO grade II and III tumors; and glioblastoma). Clinical and imaging factors such as age, Karnofsky performance score, treatment, TTPmin, and maximal tumor-to-brain ratio (TBRmax) were analyzed with regard to progression-free and overall survival (PFS and OS) via univariate and multivariate regression analysis. RESULTS: PFS and OS were longest in the IDH1/2 mut-1p/19q codel subgroup, followed by IDH1/2 mut-1p/19q non-codel, IDH1/2 wildtype, and GBM (P < 0.001). Further, outcome stratified by TTPmin with a cutoff of 17.5 minutes revealed significantly longer PFS and OS in patients with TTPmin >17.5 minutes (P < 0.001 for PFS and OS). Lower TBRmax values or the absence of 18F-FET uptake was also associated with favorable outcome in the entire group. In the subgroup analyses, longer median TTPmin was associated with improved outcome specifically in the IDH1/2 mut-1p/19q non-codel group. CONCLUSION: 18F-FET-PET-derived dynamic analysis defines prognostically distinct subgroups of IDH1/2 mutant-1p/19q non-codel gliomas which cannot be distinguished as yet by molecular marker analysis.
引用
- Suchorska B, Giese A, Biczok A, et al. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro Oncol. 2018. PMID: 29016996. doi:10.1093/neuonc/nox153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。